Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS207 + JS007 vs Toripalimab + Bevacizumab in First-line Advanced Hepatocellular Carcinoma
NCT07823348Phase 3Not yet recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
A Phase 3 trial of JS207, JS007 in hepatocellular carcinoma (HCC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
JS207JS007
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07823348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07823348.